Literature DB >> 23150269

DNA methylation and cancer.

Gopinathan Gokul1, Sanjeev Khosla.   

Abstract

Cancer has been considered a genetic disease with a wide array of well-characterized gene mutations and chromosomal abnormalities. Of late, aberrant epigenetic modifications have been elucidated in cancer, and together with genetic alterations, they have been helpful in understanding the complex traits observed in neoplasia. "Cancer Epigenetics" therefore has contributed substantially towards understanding the complexity and diversity of various cancers. However, the positioning of epigenetic events during cancer progression is still not clear, though there are some reports implicating aberrant epigenetic modifications in very early stages of cancer. Amongst the most studied aberrant epigenetic modifications are the DNA methylation differences at the promoter regions of genes affecting their expression. Hypomethylation mediated increased expression of oncogenes and hypermethylation mediated silencing of tumor suppressor genes are well known examples. This chapter also explores the correlation of DNA methylation and demethylation enzymes with cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23150269     DOI: 10.1007/978-94-007-4525-4_26

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  18 in total

Review 1.  Basic mechanics of DNA methylation and the unique landscape of the DNA methylome in metal-induced carcinogenesis.

Authors:  Jason Brocato; Max Costa
Journal:  Crit Rev Toxicol       Date:  2013-07       Impact factor: 5.635

2.  A novel interplay between HOTAIR and DNA methylation in osteosarcoma cells indicates a new therapeutic strategy.

Authors:  Xingang Li; Hongming Lu; Guilian Fan; Miao He; Yu Sun; Kai Xu; Fengjun Shi
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-20       Impact factor: 4.553

3.  Genome-wide methylation changes are associated with muscle fiber density and drip loss in male three-yellow chickens.

Authors:  Yonghong Zhang; Jiang Guo; Yan Gao; Shuling Niu; Chun Yang; Chunyan Bai; Xianzhong Yu; Zhihui Zhao
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

4.  Aberrant methylation of mutL homolog 1 is associated with increased risk of non-small cell lung cancer.

Authors:  Haochang Hu; Xiaoying Chen; Cong Zhou; Bin Li; Yong Yang; Xiuru Ying; Yiyi Mao; Yihan Zhang; Jie Zhong; Jie Dai; Hang Yu; Boyi Wu; Xiaodong Li; Tiangong Wang; Shiwei Duan
Journal:  J Clin Lab Anal       Date:  2017-12-05       Impact factor: 2.352

5.  Exploring Unconventional SAM Analogues To Build Cell-Potent Bisubstrate Inhibitors for Nicotinamide N-Methyltransferase.

Authors:  Iredia D Iyamu; Jonah Z Vilseck; Ravi Yadav; Nicholas Noinaj; Rong Huang
Journal:  Angew Chem Int Ed Engl       Date:  2022-02-23       Impact factor: 15.336

6.  Mycobacteria modulate host epigenetic machinery by Rv1988 methylation of a non-tail arginine of histone H3.

Authors:  Imtiyaz Yaseen; Prabhjot Kaur; Vinay Kumar Nandicoori; Sanjeev Khosla
Journal:  Nat Commun       Date:  2015-11-16       Impact factor: 14.919

7.  Prognostic value of Iroquois homeobox 1 methylation in non-small cell lung cancers.

Authors:  Ji Yun Lee; Won Kee Lee; Jae Yong Park; Dong Sun Kim
Journal:  Genes Genomics       Date:  2020-03-21       Impact factor: 1.839

Review 8.  Understanding the genetic liability to schizophrenia through the neuroepigenome.

Authors:  John F Fullard; Tobias B Halene; Claudia Giambartolomei; Vahram Haroutunian; Schahram Akbarian; Panos Roussos
Journal:  Schizophr Res       Date:  2016-01-27       Impact factor: 4.939

Review 9.  Adenosine kinase: A key regulator of purinergic physiology.

Authors:  Detlev Boison; Michael F Jarvis
Journal:  Biochem Pharmacol       Date:  2020-11-06       Impact factor: 5.858

10.  Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer.

Authors:  Shicheng Guo; Lixing Tan; Weilin Pu; Junjie Wu; Kuan Xu; Jinhui Wu; Qiang Li; Yanyun Ma; Jibin Xu; Li Jin; Jiucun Wang
Journal:  Clin Epigenetics       Date:  2014-03-24       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.